>Marché du diagnostic moléculaire en Asie-Pacifique, par produits (réactifs et kits, instruments et services et logiciels), technologie (spectrométrie de masse (MS), électrophorèse capillaire, séquençage de nouvelle génération (NGS), puces et microarray, méthodes basées sur la réaction en chaîne par polymérase (PCR), cytogénétique, hybridation in situ (ISH ou FISH), imagerie moléculaire et autres), application (oncologie, pharmacogénomique, microbiologie, tests prénatals, typage tissulaire, dépistage sanguin, maladies cardiovasculaires, maladies neurologiques, maladies infectieuses et autres), utilisateur final (hôpital, laboratoires cliniques et universitaires), pays (Chine, Inde, Japon, Australie, Corée du Sud, Malaisie, Singapour, Thaïlande, Indonésie, Philippines, reste de l'Asie-Pacifique) Tendances de l'industrie et prévisions jusqu'en 2028.
Analyse et perspectives du marché : Marché du diagnostic moléculaire en Asie-Pacifique
Le marché du diagnostic moléculaire devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 6,8 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 11 537,43 millions USD d'ici 2028. La demande d'outils de diagnostic moléculaire augmente pour diagnostiquer les patients atteints de COVID-19, associée à une augmentation des maladies infectieuses et de la prévalence du cancer comme moteurs de la croissance du marché du diagnostic moléculaire.
Le diagnostic moléculaire permet d'identifier ou de diagnostiquer des maladies telles que les maladies infectieuses , les maladies génétiques, les maladies cardiovasculaires, les maladies neurologiques et autres en étudiant des molécules telles que l'ADN, l'ARN, les protéines dans un tissu ou un liquide. Différentes technologies telles que la PCR, la spectrométrie de masse, le séquençage de nouvelle génération, la cytogénétique, l'hybridation in situ, l'imagerie moléculaire et d'autres sont utilisées pour diagnostiquer différentes maladies. Le diagnostic moléculaire utilise des outils puissants tels que le profilage de l'expression génétique, l'analyse de la séquence d'ADN et la détection de biomarqueurs pour déterminer la sensibilité des individus à certaines conditions ou au stade de la maladie existante. Il est devenu un élément important des hôpitaux, des laboratoires cliniques et autres, car il comprend tous les tests et méthodes permettant d'identifier une maladie et de l'analyser. Il permet d'offrir le meilleur traitement aux patients et, grâce aux nouvelles technologies, le processus de diagnostic est devenu plus rapide et plus efficace.
Des outils, instruments et kits de diagnostic moléculaire sont développés pour diagnostiquer une ou plusieurs maladies particulières à partir de fluides ou de tissus corporels. De nombreux développements technologiques lancent de nouveaux produits dotés d'une technologie hautement efficace pour offrir le meilleur traitement possible dans les délais. De plus, la demande d'outils de diagnostic moléculaire augmente pour diagnostiquer les patients atteints de COVID-19, associée à une augmentation de la prévalence des maladies infectieuses et du cancer. La demande croissante de tests au point de service est le facteur clé qui stimule le marché du diagnostic moléculaire en Asie-Pacifique. Cependant, le coût élevé de l'instrumentation et les règles strictes établies par les organismes gouvernementaux pour l'approbation des produits de diagnostic moléculaire peuvent entraver la croissance du marché du diagnostic moléculaire.
En outre, l’augmentation des financements accordés par les organismes gouvernementaux et les autorités privées pour développer des produits de diagnostic moléculaire, associée à l’augmentation des dépenses de santé et à l’adoption croissante de logiciels d’analyse pour le diagnostic moléculaire, créera d’énormes opportunités pour le marché du diagnostic moléculaire en Asie-Pacifique. Cependant, la forte concurrence sur le marché et la perturbation de la chaîne d’approvisionnement en raison de la pandémie de COVID-19 devraient mettre à l’épreuve le marché du diagnostic moléculaire en Asie-Pacifique.
Le rapport sur le marché du diagnostic moléculaire fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché du diagnostic moléculaire, contactez Data Bridge Market Research pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché du diagnostic moléculaire
Le marché du diagnostic moléculaire est segmenté en fonction des produits, de la technologie, de l'application et de l'utilisateur final. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base des produits, le marché du diagnostic moléculaire de la région Asie-Pacifique est segmenté en réactifs et kits, instruments et services et logiciels. En 2021, le segment des instruments devrait dominer le marché du diagnostic moléculaire en raison de la hausse de la demande de technologies avancées pour diagnostiquer des maladies telles que les maladies infectieuses, le cancer et autres.
- On the basis of technology, the Asia-Pacific molecular diagnostics market is segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The polymerase chain reaction (PCR)-based methods are further segmented into cold PCR, digital PCR, directlinear analysis, quantitative fluorescent PCR, real-time PCR, and reverse transcriptase PCR. The molecular imaging segment is further subdivided into optical imaging and FDG-PET. In 2021, the polymerase chain reaction (PCR)-based methods segment is expected to dominate the molecular diagnostics market due to increased demand for PCR kits to diagnose COVID-19 and curb the pandemic.
- On the basis of application, the Asia-Pacific molecular diagnostics market is segmented into oncology, pharmacogenomics, microbiology, prenatal tests, tissue typing, blood screening, cardiovascular diseases, neurological diseases, infectious diseases and others. The oncology segment is further segmented into oncology, by cancer type and oncology, by technology. The oncology, by cancer type is further sub-divided into breast cancer, colorectal cancer, lung cancer, prostate cancer and others. The oncology, by technology is further sub-segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The pharmacogenomics is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The microbiology is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The prenatal tests are further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The tissue typing is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The blood screening is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The cardiovascular diseases are further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The neurological is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging, and others. The infectious diseases are further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. In 2021, the infectious diseases segment is expected to dominate the molecular diagnostics market due to the rise in infectious diseases such as flu, COVID-19, AIDS, and others and the increased demand for highly efficient molecular diagnostics technology.
- On the basis of end users, the Asia-Pacific molecular diagnostics market is segmented into hospital, clinical laboratories and academics. In 2021, the clinical laboratories segment is expected to dominate the molecular diagnostics market due to the rising number of patients with various illnesses and the growing need for diagnostics instruments.
Asia-Pacific Molecular Diagnostics Market Country Level Analysis
Asia Pacific molecular diagnostics market is analysed, and market size information is provided by the country, products, technology, application and end user as referenced above.
The countries covered in the molecular diagnostics market report are the China, Thailand, Australia, Japan, South Korea, Singapore, Malaysia, Indonesia, Philippines, India, and Rest of Asia-Pacific are :
Products segment in China region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increase in demand for diagnosis instrument to diagnose COVID-19 patients and other cardiovascular diseases, infectious diseases and others. The products segment in India is dominating the Asia-Pacific market owing to increased healthcare expenditure. Philippines is leading the growth of the Asia-Pacific market for risk segment is dominating in this country due to increasing demand for point-of-care testing and precision medicine.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Molecular diagnostics, is Boosting the Molecular diagnostics market Growth
The molecular diagnostics market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.
Competitive Landscape and Molecular Diagnostics Market Share Analysis
Le paysage concurrentiel du marché du diagnostic moléculaire fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché du diagnostic moléculaire.
Les principales entreprises qui opèrent dans le domaine du diagnostic moléculaire sont Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BD, bioMérieux SA, Cepheid, Hologic, Inc., Life Technologies, Myriad Genetics, Inc., QIAGEN, Agilent Technologies, Inc., Quidel Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., IMMUCOR, Luminex Corporation, Meridian Bioscience, Hoffmann-La Roche Ltd et GenMark Diagnostics, Inc., entre autres acteurs nationaux. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.
De nombreux contrats, accords et lancements sont également initiés par les entreprises du monde entier qui accélèrent également le marché du diagnostic moléculaire.
Par exemple,
- En juin 2021, Thermo Fisher Scientific Inc. a lancé un nouveau produit appelé Attune CytPix, un cytomètre de flux fluorescent qui offre une imagerie améliorée et une mise au point acoustique avec une caméra haute vitesse.
- En mars 2020, Abbott a lancé un nouveau produit appelé ID NOW pour la détection du coronavirus. Il est léger, portable, offre un haut degré de précision et utilise la technologie moléculaire.
La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché renforcent l'empreinte de l'entreprise sur le marché du diagnostic moléculaire, ce qui offre également l'avantage de la croissance des bénéfices de l'organisation.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PRODUCT AND BRAND ANALYSIS: ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET
4.2 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING DEMAND FOR MOLECULAR DIAGNOSTIC TOOLS TO DIAGNOSE COVID-19
5.1.2 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER
5.1.3 RISING FUNDING FOR MOLECULAR DIAGNOSIS PRODUCTS
5.1.4 RISING DEMAND FOR POINT-OF-CARE (POC) TESTING
5.1.5 DEVELOPMENT OF COMPANION DIAGNOSTIC ASSAY AND PERSONALIZED MEDICINES
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENTATIONS
5.2.2 STRINGENT LEGAL AND REGULATORY STANDARDS ARE EXPECTED TO HAMPER THE MARKET GROWTH
5.2.3 DELAY IN APPROVAL OF EXPERIMENTAL TEST FOR MOLECULAR DIAGNOSIS
5.3 OPPORTUNITIES
5.3.1 RISING GERIATRIC POPULATION
5.3.2 INCREASING ADOPTION OF ANALYSER SOFTWARE FOR MOLECULAR DIAGNOSIS
5.3.3 RISING AWARENESS REGARDING RAPID TECHNOLOGICAL ADVANCEMENTS
5.3.4 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
1.4 CHALLENGES
5.3.5 HIGH COMPETITION AMONG MARKET PLAYERS
5.3.6 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET
6.1 ANALYSIS ON IMPACT OF COVID-19 ON THE ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET
6.2 AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVES FOR GROWTH OF THE MOLECULAR DIAGNOSTICS MARKET
6.3 IMPACT ON DEMAND
6.4 IMPACT ON SUPPLY CHAIN
6.5 IMPACT ON PRICE
6.6 STRATEGIC INITIATIVES BY MANUFACTURERS
6.7 THE RISING COVID-19 CASES IS LEADING THE MOLECULAR DIAGNOSTICS MARKET
6.8 CONCLUSION
7 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 FULLY AUTOMATED INSTRUMENTS
7.2.2 SEMI-AUTOMATED INSTRUMENTS
7.3 REAGENTS AND KITS
7.4 SERVICES AND SOFTWARES
8 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
8.2.1 REAL-TIME PCR
8.2.2 DIGITAL PCR
8.2.3 REVERSE TRANSCRIPTASE PCR
8.2.4 QUANTITATIVE FLUORESCENT PCR
8.2.5 DIRECT LINEAR ANALYSIS
8.2.6 COLD PCR
8.3 NEXT GENERATION SEQUENCING (NGS)
8.4 CYTOGENETICS
8.5 CAPILLARY ELECTROPHORESIS
8.6 IN SITU HYBRIDIZATION (ISH OR FISH)
8.7 MOLECULAR IMAGING
8.7.1 OPTICAL IMAGING
8.7.2 FDG-PET
8.8 MASS SPECTROMETRY (MS)
8.9 CHIPS AND MICROARRAY
8.1 OTHERS
9 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 INFECTIOUS DISEASES
9.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.2.2 NEXT GENERATION SEQUENCING (NGS)
9.2.3 CYTOGENETICS
9.2.4 CAPILLARY ELECTROPHORESIS
9.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.2.6 MOLECULAR IMAGING
9.2.7 MASS SPECTROMETRY (MS)
9.2.8 CHIPS AND MICROARRAY
9.2.9 OTHERS
9.3 MICROBIOLOGY
9.3.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.3.2 NEXT GENERATION SEQUENCING (NGS)
9.3.3 CYTOGENETICS
9.3.4 CAPILLARY ELECTROPHORESIS
9.3.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.3.6 MOLECULAR IMAGING
9.3.7 MASS SPECTROMETRY (MS)
9.3.8 CHIPS AND MICROARRAY
9.3.9 OTHERS
9.4 BLOOD SCREENING
9.4.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.4.2 NEXT GENERATION SEQUENCING (NGS)
9.4.3 CYTOGENETICS
9.4.4 CAPILLARY ELECTROPHORESIS
9.4.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.4.6 MOLECULAR IMAGING
9.4.7 MASS SPECTROMETRY (MS)
9.4.8 CHIPS AND MICROARRAY
9.4.9 OTHERS
9.5 ONCOLOGY
9.5.1 ONCOLOGY, BY CANCER TYPE
9.5.1.1 BREAST CANCER
9.5.1.2 COLORECTAL CANCER
9.5.1.3 LUNG CANCER
9.5.1.4 PROSTATE CANCER
9.5.1.5 OTHERS
9.5.2 ONCOLOGY, BY TECHNOLOGY
9.5.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.5.2.2 NEXT GENERATION SEQUENCING (NGS)
9.5.2.3 CYTOGENETICS
9.5.2.4 CAPILLARY ELECTROPHORESIS
9.5.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.5.2.6 MOLECULAR IMAGING
9.5.2.7 MASS SPECTROMETRY (MS)
9.5.2.8 CHIPS AND MICROARRAY
9.5.2.9 OTHERS
9.6 TISSUE TYPING
9.6.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.6.2 NEXT GENERATION SEQUENCING (NGS)
9.6.3 CYTOGENETICS
9.6.4 CAPILLARY ELECTROPHORESIS
9.6.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.6.6 MOLECULAR IMAGING
9.6.7 MASS SPECTROMETRY (MS)
9.6.8 CHIPS AND MICROARRAY
9.6.9 OTHERS
9.7 PHARMACOGENOMICS
9.7.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.7.2 NEXT GENERATION SEQUENCING (NGS)
9.7.3 CYTOGENETICS
9.7.4 CAPILLARY ELECTROPHORESIS
9.7.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.7.6 MOLECULAR IMAGING
9.7.7 MASS SPECTROMETRY (MS)
9.7.8 CHIPS AND MICROARRAY
9.7.9 OTHERS
9.8 PRENATAL TESTS
9.8.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.8.2 NEXT GENERATION SEQUENCING (NGS)
9.8.3 CYTOGENETICS
9.8.4 CAPILLARY ELECTROPHORESIS
9.8.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.8.6 MOLECULAR IMAGING
9.8.7 MASS SPECTROMETRY (MS)
9.8.8 CHIPS AND MICROARRAY
9.8.9 OTHERS
9.9 NEUROLOGICAL DISEASES
9.9.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.9.2 NEXT GENERATION SEQUENCING (NGS)
9.9.3 CYTOGENETICS
9.9.4 CAPILLARY ELECTROPHORESIS
9.9.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.9.6 MOLECULAR IMAGING
9.9.7 MASS SPECTROMETRY (MS)
9.9.8 CHIPS AND MICROARRAY
9.9.9 OTHERS
9.1 CARDIOVASCULAR DISEASES
9.10.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.10.2 NEXT GENERATION SEQUENCING (NGS)
9.10.3 CYTOGENETICS
9.10.4 CAPILLARY ELECTROPHORESIS
9.10.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.10.6 MOLECULAR IMAGING
9.10.7 MASS SPECTROMETRY (MS)
9.10.8 CHIPS AND MICROARRAY
9.10.9 OTHERS
9.11 OTHERS
9.11.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.11.2 NEXT GENERATION SEQUENCING (NGS)
9.11.3 CYTOGENETICS
9.11.4 CAPILLARY ELECTROPHORESIS
9.11.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.11.6 MOLECULAR IMAGING
9.11.7 MASS SPECTROMETRY (MS)
9.11.8 CHIPS AND MICROARRAY
9.11.9 OTHERS
10 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
11 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 INDIA
11.1.4 SOUTH KOREA
11.1.5 AUSTRALIA
11.1.6 MALAYSIA
11.1.7 THAILAND
11.1.8 INDONESIA
11.1.9 SINGAPORE
11.1.10 PHILIPPINES
11.1.11 REST OF ASIA-PACIFIC
12 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
13 SWOT
14 COMPANY PROFILES
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 ILLUMINA, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 HOLOGIC, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BIOMÉRIEUX SA
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 REVENUE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BD
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 BECKMAN COULTER, INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BIO-RAD LABORATORIES, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENTS
14.1 CEPHEID
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 GENMARK DIAGNOSTICS, INC.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 IMMUCOR
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 LIFE TECHNOLOGIES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 LUMINEX CORPORATION
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 MERRIDIAN BIOSCIENCE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 MYRIAD GENETICS, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 QIAGEN
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 QUIDEL CORPORATION
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 SIEMENS HEALTHCARE GMBH
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
LIST OF TABLES
TABLE 1 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 2 ASIA PACIFIC INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 ASIA PACIFIC INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 ASIA PACIFIC REAGENTS AND KITS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA PACIFIC SERVICES AND SOFTWARES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 7 ASIA PACIFIC POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA PACIFIC POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 9 ASIA PACIFIC NEXT GENERATION SEQUENCING (NGS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA PACIFIC CYTOGENETICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA PACIFIC CAPILLARY ELECTROPHORESIS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA PACIFIC INS SITU HYBRIDIZATION (ISH OR FISH) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA PACIFIC MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 15 ASIA PACIFIC MASS SPECTROMETRY (MS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC CHIPS AND MICROARRAY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 ASIA PACIFIC INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 25 ASIA PACIFIC ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 ASIA PACIFIC TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA PACIFIC PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC CLINICAL LABORATORIES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC HOSPITAL IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC ACADEMICS IN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 CHINA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 CHINA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 65 CHINA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 66 CHINA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 67 CHINA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 68 CHINA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 CHINA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 70 CHINA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 71 CHINA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 CHINA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 CHINA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 74 CHINA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 CHINA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 CHINA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 77 CHINA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 78 CHINA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 79 CHINA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 80 CHINA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 JAPAN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 82 JAPAN INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 83 JAPAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 84 JAPAN POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 85 JAPAN MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 JAPAN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 87 JAPAN ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 89 JAPAN PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 JAPAN MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 JAPAN PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 92 JAPAN TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 93 JAPAN BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 94 JAPAN CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 JAPAN NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 96 JAPAN INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 97 JAPAN OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 98 JAPAN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 INDIA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 100 INDIA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 101 INDIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 102 INDIA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 103 INDIA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 104 INDIA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 INDIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 106 INDIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 107 INDIA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 108 INDIA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 109 INDIA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 110 INDIA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 111 INDIA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 INDIA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 INDIA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 114 INDIA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 115 INDIA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 116 INDIA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 117 SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 118 SOUTH KOREA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 119 SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 120 SOUTH KOREA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 121 SOUTH KOREA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 122 SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 SOUTH KOREA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 124 SOUTH KOREA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 125 SOUTH KOREA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 126 SOUTH KOREA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 127 SOUTH KOREA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 128 SOUTH KOREA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 129 SOUTH KOREA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 130 SOUTH KOREA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 131 SOUTH KOREA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 132 SOUTH KOREA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 133 SOUTH KOREA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 134 SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 135 AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 136 AUSTRALIA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 137 AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 138 AUSTRALIA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 139 AUSTRALIA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 140 AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 141 AUSTRALIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRALIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 143 AUSTRALIA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 144 AUSTRALIA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 145 AUSTRALIA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 AUSTRALIA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 147 AUSTRALIA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 148 AUSTRALIA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 149 AUSTRALIA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 150 AUSTRALIA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 AUSTRALIA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 152 AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 MALAYSIA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 154 MALAYSIA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 155 MALAYSIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 156 MALAYSIA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 157 MALAYSIA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 158 MALAYSIA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 159 MALAYSIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 160 MALAYSIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 161 MALAYSIA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 162 MALAYSIA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 163 MALAYSIA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 164 MALAYSIA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 165 MALAYSIA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 166 MALAYSIA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 167 MALAYSIA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 168 MALAYSIA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 169 MALAYSIA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 170 MALAYSIA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 171 THAILAND MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 172 THAILAND INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 173 THAILAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 174 THAILAND POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 175 THAILAND MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 176 THAILAND MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 177 THAILAND ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 178 THAILAND ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 179 THAILAND PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 180 THAILAND MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 181 THAILAND PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 182 THAILAND TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 THAILAND BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 184 THAILAND CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 185 THAILAND NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 186 THAILAND INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 187 THAILAND OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 188 THAILAND MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 189 INDONESIA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 190 INDONESIA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 191 INDONESIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 192 INDONESIA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 193 INDONESIA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 194 INDONESIA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 195 INDONESIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 196 INDONESIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 197 INDONESIA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 198 INDONESIA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 199 INDONESIA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 200 INDONESIA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 201 INDONESIA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 202 INDONESIA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 203 INDONESIA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 204 INDONESIA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 205 INDONESIA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 206 INDONESIA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 207 SINGAPORE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 208 SINGAPORE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 209 SINGAPORE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 210 SINGAPORE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 211 SINGAPORE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 212 SINGAPORE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 213 SINGAPORE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 214 SINGAPORE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 215 SINGAPORE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 216 SINGAPORE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 217 SINGAPORE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 218 SINGAPORE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 219 SINGAPORE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 220 SINGAPORE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 221 SINGAPORE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 222 SINGAPORE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 223 SINGAPORE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 224 SINGAPORE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 225 PHILIPPINES MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 226 PHILIPPINES INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 227 PHILIPPINES MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 228 PHILIPPINES POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 229 PHILIPPINES MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 230 PHILIPPINES MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 231 PHILIPPINES ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 232 PHILIPPINES ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 233 PHILIPPINES PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 234 PHILIPPINES MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 235 PHILIPPINES PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 236 PHILIPPINES TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 237 PHILIPPINES BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 238 PHILIPPINES CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 239 PHILIPPINES NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 240 PHILIPPINES INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 241 PHILIPPINES OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 242 PHILIPPINES MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 243 REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Liste des figures
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET AND GROWING WITH THE HIGHEST SHARE IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET
FIGURE 14 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 15 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020
FIGURE 16 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020
FIGURE 17 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 18 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 19 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 20 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 21 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 22 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET: BY PRODUCT (2021 & 2028)
FIGURE 23 ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
